Provision of ‘Methods of identifying economic evaluations of durability and treatment response

Tender description

The Welsh Government has committed to develop an All-Wales Cell and Gene Therapy Strategy and has commissioned the Welsh Blood Service (as part of the Velindre NHS Trust) to support the development of this work. The programme launched in 2018, with the key objectives of the strategy being: • Implement & secure healthcare value & patient benefit • Support development of skilled workforce • Increase research in Wales (Inc. clinical trials) • Support increased innovation > commercialisation of products & services • Accelerate adoption of new technology • Support economic development, business growth & job creation • Position Wales as key partner in UK-International collaborative work The requirement is for a consultant / consultancy to work on behalf of the Welsh Blood Service within the MW-ATTC programme to develop the work as described below for a period of 4 months, starting from March 2021 through to and including June 2021 for the completion of Phase 1 (Phase 1 not exceeding 50% of total project costs and with the option to extend into Phases 2 ,3 and 4 for further 7 months) in order to support the identification of methods for deriving plausible assumptions of durability of treatment response and evidence that value attributes linked to ATMPs are deemed rewardable by society and to develop / establish a White Paper(s) on the ‘Methods of Identifying Economic Evaluation of Durability and Treatment Response’ and ‘Value attributes linked to ATMPs are deemed rewardable by society’.